Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"HilleVax","sponsor":"Frazier Healthcare","pharmaFlowCategory":"D","amount":"$135.0 million","upfrontCash":"Undisclosed","newsHeadline":"HilleVax Closes $135 Million Crossover Financing to Advance Clinical Stage Norovirus Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"HilleVax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HilleVax Announces Results from 5-Year Clinical Study Supporting Long-Term Immunogenicity of HIL-214 Norovirus Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"HilleVax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HilleVax Announces Positive Recommendation from Safety Data Monitoring Committee for NEST-IN1 Phase 2b Clinical Trial of HIL-214 Norovirus Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"HilleVax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HilleVax Announces Positive Immunogenicity Results for Run-In Cohort of NEST-IN1 Phase 2b Clinical Trial of HIL-214 Norovirus Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"HilleVax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HilleVax Announces Completion of Enrollment of NEST-IN1 Phase 2b Clinical Study of HIL-214 Norovirus Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"HilleVax","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"HilleVax Announces Pricing of Public Offering of Common Stock","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"HilleVax","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$115.0 million","upfrontCash":"Undisclosed","newsHeadline":"HilleVax Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters\u2122 Option to Purchase Additional Shares","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"HilleVax","sponsor":"Chengdu Kanghua Biological Products","pharmaFlowCategory":"D","amount":"$270.5 million","upfrontCash":"$15.0 million","newsHeadline":"HilleVax and Kangh Announce Exclusive License Agreement for Hexavalent VLP Norovirus Vaccine Candidate Outside of China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by HilleVax

    Menu

    HilleVax

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              HilleVax

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              HilleVax and Kangh Announce Exclusive License Agreement for Hexavalent VLP Norovirus Vaccine Candidate Outside of China

              Details:

              Under the agreement, HilleVax gain rights to Kangh’s hexavalent virus-like particle (VLP) vaccine candidate for norovirus, referred to by HilleVax as HIL-216, outside of Greater China.

              Lead Product(s): HIL-216

              Therapeutic Area: Infections and Infectious Diseases Product Name: HIL-216

              Highest Development Status: Preclinical Product Type: Vaccine

              Recipient: Chengdu Kanghua Biological Products

              Deal Size: $270.5 million Upfront Cash: $15.0 million

              Deal Type: Licensing Agreement January 08, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              HilleVax

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              HilleVax Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters™ Option to Purchase Additional Shares

              Details:

              HilleVax intends to use the net proceeds from the offering to fund the clinical development of HIL-214, a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.

              Lead Product(s): HIL-214

              Therapeutic Area: Infections and Infectious Diseases Product Name: HIL-214

              Highest Development Status: Phase II Product Type: Vaccine

              Partner/Sponsor/Collaborator: J.P. Morgan

              Deal Size: $115.0 million Upfront Cash: Undisclosed

              Deal Type: Public Offering September 25, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              HilleVax

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              HilleVax Announces Pricing of Public Offering of Common Stock

              Details:

              HilleVax intends to use the net proceeds from the offering to fund the clinical development of HIL-214, a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.

              Lead Product(s): HIL-214

              Therapeutic Area: Infections and Infectious Diseases Product Name: HIL-214

              Highest Development Status: Phase II/ Phase III Product Type: Vaccine

              Partner/Sponsor/Collaborator: J.P. Morgan

              Deal Size: $100.0 million Upfront Cash: Undisclosed

              Deal Type: Public Offering September 19, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              HilleVax

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              HilleVax Announces Completion of Enrollment of NEST-IN1 Phase 2b Clinical Study of HIL-214 Norovirus Vaccine Candidate

              Details:

              HIL-214, its investigational virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe norovirus-related acute gastroenteritis (AGE) in infants.

              Lead Product(s): HIL-214

              Therapeutic Area: Infections and Infectious Diseases Product Name: HIL-214

              Highest Development Status: Phase II/ Phase III Product Type: Vaccine

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 25, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              HilleVax

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              HilleVax Announces Positive Immunogenicity Results for Run-In Cohort of NEST-IN1 Phase 2b Clinical Trial of HIL-214 Norovirus Vaccine Candidate

              Details:

              HIL-214 is a VLP based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. Norovirus is the most common cause of viral acute gastroenteritis (AGE) worldwide.

              Lead Product(s): HIL-214

              Therapeutic Area: Infections and Infectious Diseases Product Name: HIL-214

              Highest Development Status: Phase II Product Type: Vaccine

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 05, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              HilleVax

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              HilleVax Announces Positive Recommendation from Safety Data Monitoring Committee for NEST-IN1 Phase 2b Clinical Trial of HIL-214 Norovirus Vaccine Candidate

              Details:

              The primary objective of the trial is to evaluate the protective efficacy of HIL-214 against the first confirmed moderate or severe AGE event due to a HIL-214 vaccine strain, GI.1 or GII.4, that occurs prior to each subject reaching 12 months of age.

              Lead Product(s): HIL-214

              Therapeutic Area: Infections and Infectious Diseases Product Name: HIL-214

              Highest Development Status: Phase II/ Phase III Product Type: Vaccine

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 31, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              HilleVax

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              HilleVax Announces Results from 5-Year Clinical Study Supporting Long-Term Immunogenicity of HIL-214 Norovirus Vaccine Candidate

              Details:

              HIL-214 is bivalent vaccine candidate in development for prevention of AGE caused by norovirus infection, consists of virus-like particles which are designed to mimic structure of two major genotypes of norovirus, GI.1 and GII.4, and is co-formulated with an alum adjuvant.

              Lead Product(s): HIL-214

              Therapeutic Area: Infections and Infectious Diseases Product Name: HIL-214

              Highest Development Status: Phase II Product Type: Vaccine

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 20, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              HilleVax

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              HilleVax Closes $135 Million Crossover Financing to Advance Clinical Stage Norovirus Vaccine Candidate

              Details:

              The proceeds of this financing support the further clinical development of HilleVax’s virus-like particle (VLP) based vaccine candidate, HIL-214, for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.

              Lead Product(s): HIL-214

              Therapeutic Area: Infections and Infectious Diseases Product Name: HIL-214

              Highest Development Status: Phase II Product Type: Vaccine

              Partner/Sponsor/Collaborator: Frazier Healthcare

              Deal Size: $135.0 million Upfront Cash: Undisclosed

              Deal Type: Financing September 08, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY